MedTrace Logo

Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression

NCT06429514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2024-05-28

No results posted yet for this study

Summary

To clarify the clinical effect of Ganoderma lucidum spore powder intervention on postoperative depressive symptoms of papillary thyroid carcinoma ; to elucidate the antidepressant mechanism of Ganoderma lucidum spore powder.

Conditions

Interventions

DIETARY_SUPPLEMENT

Ganoderma lucidum spore powder

One bag at a time, 2 times a day, 2g / bag

OTHER

placebo

One bag at a time, 2 times a day, 2g / bag

Sponsors & Collaborators

  • Zhejiang Shouxiangu Pharmaceutical Co,. Ltd.

    collaborator INDUSTRY

  • Ling Zhiqiang

    lead OTHER

Principal Investigators

  • Jinbiao Shang · Zhejiang Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2024-05-03
Completion
2024-05-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429514 on ClinicalTrials.gov